Incyte | Efectivo Y Equivalentes



Cash And Equivalent Cambio Fecha
Acadia Pharmaceuticals USD 755.99M 190.66M 2024-12
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
Alnylam Pharmaceuticals USD 966.43M 133.49M 2024-12
Amgen USD 11.97B 2.96B 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Exelixis USD 217.37M 40.97M 2025-01
Gilead Sciences USD 9.99B 4.95B 2024-12
Incyte USD 1.69B 383.72M 2024-12
Ionis Pharmaceuticals USD 242.08M 92.53M 2024-12
MacroGenics USD 179.62M 95.69M 2024-09
Merck USD 13.24B 1.35B 2024-12
Moderna USD 1.93B 283M 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Novartis USD 11.46B 2.15B 2024-12
Pfizer USD 1.04B 49M 2024-12
PTC Therapeutics USD 779.71M 253.71M 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Sarepta Therapeutics USD 1.1B 905.16M 2024-12
Ultragenyx Pharmaceutical USD 173.73M 23.11M 2024-12
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Incyte Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.